share_log

歌禮製藥-B：翌日披露報表

ASCLETIS-B: Next Day Disclosure Return

香港交易所 ·  Feb 1 18:23
Summary by Futu AI
歌禮製藥有限公司於2024年2月1日向香港聯合交易所有限公司提交了翌日披露報表，披露了自2023年12月19日至2024年2月1日期間的股份購回活動。該公司在此期間共購回了62,371,000股普通股，佔其已發行股份的5.7372%。最後一次購回發生在2024年2月1日，當日購回了750,000股，每股價格介於HKD 1.69至HKD 1.78之間，總計花費HKD 1,309,280。歌禮製藥確認，所有購回活動均獲得董事會正式授權批准，並符合香港聯交所的相關規則。
歌禮製藥有限公司於2024年2月1日向香港聯合交易所有限公司提交了翌日披露報表，披露了自2023年12月19日至2024年2月1日期間的股份購回活動。該公司在此期間共購回了62,371,000股普通股，佔其已發行股份的5.7372%。最後一次購回發生在2024年2月1日，當日購回了750,000股，每股價格介於HKD 1.69至HKD 1.78之間，總計花費HKD 1,309,280。歌禮製藥確認，所有購回活動均獲得董事會正式授權批准，並符合香港聯交所的相關規則。
ACEA PHARMACEUTICALS LIMITED FILED THE FOLLOWING DAY DISCLOSURE REPORT WITH THE HONG KONG STOCK EXCHANGE LIMITED ON 1 FEBRUARY 2024 DISCLOSING ITS SHARE REPURCHASE ACTIVITIES FOR THE PERIOD FROM 19 DECEMBER 2023 TO 1 FEBRUARY 2024. The company repurchased a total of 62,371,000 shares of common stock during this period, representing 5.7372% of its issued shares. The last repurchase took place on February 1, 2024, and 750,000 shares were repurchased on that date, priced between HKD 1.69 and HKD 1.78, at a total cost of HKD 1,309,280. ACARA PHARMACEUTICALS CONFIRMS THAT ALL BUYBACKS HAVE BEEN FORMALLY AUTHORISED BY THE BOARD OF DIRECTORS AND COMPLY WITH THE RELEVANT RULES OF THE HKEX.
ACEA PHARMACEUTICALS LIMITED FILED THE FOLLOWING DAY DISCLOSURE REPORT WITH THE HONG KONG STOCK EXCHANGE LIMITED ON 1 FEBRUARY 2024 DISCLOSING ITS SHARE REPURCHASE ACTIVITIES FOR THE PERIOD FROM 19 DECEMBER 2023 TO 1 FEBRUARY 2024. The company repurchased a total of 62,371,000 shares of common stock during this period, representing 5.7372% of its issued shares. The last repurchase took place on February 1, 2024, and 750,000 shares were repurchased on that date, priced between HKD 1.69 and HKD 1.78, at a total cost of HKD 1,309,280. ACARA PHARMACEUTICALS CONFIRMS THAT ALL BUYBACKS HAVE BEEN FORMALLY AUTHORISED BY THE BOARD OF DIRECTORS AND COMPLY WITH THE RELEVANT RULES OF THE HKEX.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.